Fig. 3
From: Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine
Effects of gemcitabine and AZD7762 on cell cycle distribution. a UCCs were treated for 24 or 48 h with gemcitabine (10 nM) and/or AZD7762 (10 nM in RT-112 and T24 cells, and 20 nM in VM-CUB1 and UM-UC-3 cells) before cell cycle distribution was analysed by flow cytometry. DMSO served as a solvent control. b Cyclin E protein expression subsequent to gemcitabine and/or AZD7762 treatment was evaluated by Western blot analysis